Michael McElhaugh
Chief Executive Officer presso ARBUTUS BIOPHARMA CORPORATION
Patrimonio netto: 4 M $ in data 31/03/2024
Profilo
Michael J.
McElhaugh was the founder of Arbutus Biopharma, Inc. (founded in 2012) where he held the title of Chief Operating Officer.
He is currently the President, Chief Executive Officer, COO & Director at Arbutus Biopharma Corp.
(since 2014) and the President & Chief Executive Officer at Arbutus Biopharma, Inc. (since 2024).
In his former positions, he was the Director-Hepatitis C Worldwide Commercialization at Bristol Myers Squibb Co. and the Director-Business Development at Pharmasset, Inc. (from 2008 to 2012).
Mr. McElhaugh has a graduate degree from Thomas Jefferson University, an undergraduate degree from St. Joseph's University, and an MBA from Johnson Graduate School of Management.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 02/02/2024 | 1 504 793 ( 0.84% ) | 4 M $ | 31/03/2024 |
Posizioni attive di Michael McElhaugh
| Società | Posizione | Inizio |
|---|---|---|
| ARBUTUS BIOPHARMA CORPORATION | Chief Executive Officer | 01/01/2024 |
Arbutus Biopharma, Inc.
 Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Chief Executive Officer | 01/01/2024 |
Precedenti posizioni note di Michael McElhaugh
| Società | Posizione | Fine |
|---|---|---|
Pharmasset, Inc.
 Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Corporate Officer/Principal | 01/03/2012 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Arbutus Biopharma, Inc.
Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Founder | - |
Formazione di Michael McElhaugh
| Thomas Jefferson University | Graduate Degree |
| St. Joseph's University | Undergraduate Degree |
| Johnson Graduate School of Management | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| ARBUTUS BIOPHARMA CORPORATION | Health Technology |
| Aziende private | 2 |
|---|---|
Pharmasset, Inc.
Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Health Technology |
Arbutus Biopharma, Inc.
Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Health Technology |
- Borsa valori
- Insiders
- Michael McElhaugh
